

Highly Specialised Technology Committee Interests Register

Topic: Eflornithine for treating high-risk neuroblastoma with complete or partial response after immunotherapy [ID4060]

Publication Date: TBC

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Emtiyaz Chowdhury	HST Committee Member	Non-Financial Professional Interests	I am employed by Parexel. Parexel is a CRO that provides services to both manufacturers. I have not been directly involved in any work related to these specific technologies.	10/03/2025	It was agreed that Emtiyaz's declaration would not prevent them from participating in discussions on this appraisal
Juliet Gray	Clinical Expert	Financial Interests	I have previously provided consultancy advice to Norgine, to provide advice about eflornithine. This was most recently in January 2023, and in total my income from the work was less than £5000. I have no on going financial or other interests in the company or eflornithine.	02/01/2025	It was agreed that Juliet's declaration would not prevent them from providing expert advice to the committee
Juliet Gray	Clinical Expert	Indirect Interests	<ul style="list-style-type: none"> Consultancy work with other companies: Recordati Rare Diseases; advisory board, most recently July 2023 YmAbs; advisory board, paid educational events and member of independent data monitoring committee. Most recently May 2023 Servier ; advisory board, ½ day Dec 2023 Chair of the UK Neuroblastoma group 	02/01/2025	It was agreed that Juliet's declaration would not prevent them from providing expert advice to the committee

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			<ul style="list-style-type: none"> • Vice president of the European Neuroblastoma Research Network (SIOPEX) • Member of scientific advisory boards for several charities (Solving Kids Cancer, Neuroblastoma Australia and Friends of Rosie) 		
Nicholas Bird	Patient Expert	Non-Financial Professional Interests	<ul style="list-style-type: none"> • I am involved in research activities of SIOPEX the European Neuroblastoma Research Network which includes discussions on incorporation of DFMO into treatment protocols. • I am a Patient & Public Voice Partner for NHS England Clinical Reference Group for Children and Young People's Cancers. • My son was treated by Dr. Giselle Sholler, Chair and Founder of the Beat Childhood Cancer (BeatCC) Research Consortium, from July 2012 to July 2013. 	26/09/2024	It was agreed that Nicholas' declaration would not prevent them from providing expert advice to the committee
Nicholas Bird	Patient Expert	Indirect Interests	Solving Kids' Cancer UK has received sponsorship for parent education activities from Norgine.	26/09/2024	It was agreed that Nicholas' declaration would not prevent them from providing expert advice to the committee